VB-111 is a targeted anti-cancer biologic agent that is positioned to potentially treat a wide range of solid tumors with current clinical trials in rGBM, thyroid cancer and ovarian cancer.

VBL launched the OVAL Phase 3 pivotal registration trial, studying VB-111 in platinum-resistant ovarian cancer in December 2017. The OVAL study will be conducted in collaboration with the GOG Foundation, Inc., a leading organization for research excellence in the field of gynecologic malignancies.